FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2585750147> ?p ?o ?g. }

• W2585750147 endingPage "3291" @default.
• W2585750147 startingPage "3291" @default.
• W2585750147 abstract "Abstract Background and aim: Current therapeutic protocols for adult ALL consider MRD together with the baseline risk factors (age, WBC count, immunophenotype, cytogenetics) and speed in response to therapy for treatment decisions. On the other hand, the systematic use of allogeneic SCT for all adult patients (pts) with Ph- HR-ALL is still a matter of debate. The aim of the prospective study ALL-AR-03 from the Spanish PETHEMA Group was to evaluate the response to a differentiated therapy (chemotherapy or allogeneic SCT) according to early bone marrow blast clearance and MRD levels (assessed by cytofluorometry at the end of induction and consolidation therapy) in HR Ph- adult ALL patients. Patients and methods: HR ALL included one or more of the following baseline parameters: age 30–60 yr, WBC count >25x109/L and 11q23 or MLL rearrangements. Induction therapy included vincristine, prednisone and daunorubicin for 4 weeks. In pts with slow cytologic response to therapy (≥10% blasts in bone marrow assessed on d14) intensified induction with high dose ARA-C and mitoxantrone was administered. Early consolidation therapy included 3 cycles with rotating cytotoxic drugs including high-dose methotrexate, high-dose ARA-C and high-dose asparaginase. Pts. with slow cytologic response on d14 or MRD level >0.05% after consolidation were assigned to allogeneic SCT (related or unrelated) and those with standard cytologic response on d14 and MRD level <0.05% after consolidation received 3 additional cycles of delayed consolidation (identical to those of early consolidation) followed by maintenance therapy up to 2yr in CR. Results: On June 2008,192 patients were evaluable (mean (SD) age 37(10) yr, 105 males, 119 precursor B-ALL, 73 T-ALL, WBC count 65(99) x109/L). Induction death: 17(9%), resistance: 12 (6%), CR: 163 (85%). MRD<0.1% was observed in 64% of CR patients. Early consolidation was completed in 126 patients. MRD<0.05% was observed in 65% at the end of consolidation. On June 2008, allogeneic SCT was performed to 30 pts (15 from HLA-identical siblings and 15 MUD), TRM 11 pts, relapse 4, CCR 15. Delayed consolidation and maintenance was administered to 79 pts (toxic death 4 pts, relapse 21, CCR 54). Four-yr DFS for the whole series was 36±7% (37±19% for pts assigned to SCT and 56±12% for those assigned to chemotherapy). Slow cytologic response was associated with a lower CR probability and higher induction death. No baseline variable was associated with a higher probability of MRD negativity after induction or consolidation. Conclusions: These results suggest that in HR Ph- adult ALL pts with adequate response to induction and adequate clearance of MDR the results of therapy are not hampered by avoiding allogeneic SCT. Supported by grants P-EF/07 from FIJC and RD 06/0020/1014 from Instituto Carlos III" @default.
• W2585750147 created "2017-02-10" @default.
• W2585750147 creator A5003682435 @default.
• W2585750147 creator A5003740257 @default.
• W2585750147 creator A5004401859 @default.
• W2585750147 creator A5006173909 @default.
• W2585750147 creator A5008564951 @default.
• W2585750147 creator A5011772396 @default.
• W2585750147 creator A5014009900 @default.
• W2585750147 creator A5014775908 @default.
• W2585750147 creator A5017225753 @default.
• W2585750147 creator A5020697648 @default.
• W2585750147 creator A5024617467 @default.
• W2585750147 creator A5027815550 @default.
• W2585750147 creator A5028965719 @default.
• W2585750147 creator A5029238392 @default.
• W2585750147 creator A5033227605 @default.
• W2585750147 creator A5041309879 @default.
• W2585750147 creator A5045301478 @default.
• W2585750147 creator A5054706356 @default.
• W2585750147 creator A5054952877 @default.
• W2585750147 creator A5058799782 @default.
• W2585750147 creator A5063931881 @default.
• W2585750147 creator A5068410222 @default.
• W2585750147 creator A5069688230 @default.
• W2585750147 creator A5080587560 @default.
• W2585750147 creator A5082351468 @default.
• W2585750147 creator A5085969689 @default.
• W2585750147 creator A5089188528 @default.
• W2585750147 creator A5089353610 @default.
• W2585750147 date "2008-11-16" @default.
• W2585750147 modified "2023-10-18" @default.
• W2585750147 title "Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial." @default.
• W2585750147 doi "https://doi.org/10.1182/blood.v112.11.3291.3291" @default.
• W2585750147 hasPublicationYear "2008" @default.
• W2585750147 type Work @default.
• W2585750147 sameAs 2585750147 @default.
• W2585750147 citedByCount "2" @default.
• W2585750147 crossrefType "journal-article" @default.
• W2585750147 hasAuthorship W2585750147A5003682435 @default.
• W2585750147 hasAuthorship W2585750147A5003740257 @default.
• W2585750147 hasAuthorship W2585750147A5004401859 @default.
• W2585750147 hasAuthorship W2585750147A5006173909 @default.
• W2585750147 hasAuthorship W2585750147A5008564951 @default.
• W2585750147 hasAuthorship W2585750147A5011772396 @default.
• W2585750147 hasAuthorship W2585750147A5014009900 @default.
• W2585750147 hasAuthorship W2585750147A5014775908 @default.
• W2585750147 hasAuthorship W2585750147A5017225753 @default.
• W2585750147 hasAuthorship W2585750147A5020697648 @default.
• W2585750147 hasAuthorship W2585750147A5024617467 @default.
• W2585750147 hasAuthorship W2585750147A5027815550 @default.
• W2585750147 hasAuthorship W2585750147A5028965719 @default.
• W2585750147 hasAuthorship W2585750147A5029238392 @default.
• W2585750147 hasAuthorship W2585750147A5033227605 @default.
• W2585750147 hasAuthorship W2585750147A5041309879 @default.
• W2585750147 hasAuthorship W2585750147A5045301478 @default.
• W2585750147 hasAuthorship W2585750147A5054706356 @default.
• W2585750147 hasAuthorship W2585750147A5054952877 @default.
• W2585750147 hasAuthorship W2585750147A5058799782 @default.
• W2585750147 hasAuthorship W2585750147A5063931881 @default.
• W2585750147 hasAuthorship W2585750147A5068410222 @default.
• W2585750147 hasAuthorship W2585750147A5069688230 @default.
• W2585750147 hasAuthorship W2585750147A5080587560 @default.
• W2585750147 hasAuthorship W2585750147A5082351468 @default.
• W2585750147 hasAuthorship W2585750147A5085969689 @default.
• W2585750147 hasAuthorship W2585750147A5089188528 @default.
• W2585750147 hasAuthorship W2585750147A5089353610 @default.
• W2585750147 hasConcept C126322002 @default.
• W2585750147 hasConcept C143998085 @default.
• W2585750147 hasConcept C2776694085 @default.
• W2585750147 hasConcept C2776755627 @default.
• W2585750147 hasConcept C2778461978 @default.
• W2585750147 hasConcept C2779429289 @default.
• W2585750147 hasConcept C2779823535 @default.
• W2585750147 hasConcept C2780007613 @default.
• W2585750147 hasConcept C2780923524 @default.
• W2585750147 hasConcept C2781107101 @default.
• W2585750147 hasConcept C2909962599 @default.
• W2585750147 hasConcept C71924100 @default.
• W2585750147 hasConcept C90924648 @default.
• W2585750147 hasConceptScore W2585750147C126322002 @default.
• W2585750147 hasConceptScore W2585750147C143998085 @default.
• W2585750147 hasConceptScore W2585750147C2776694085 @default.
• W2585750147 hasConceptScore W2585750147C2776755627 @default.
• W2585750147 hasConceptScore W2585750147C2778461978 @default.
• W2585750147 hasConceptScore W2585750147C2779429289 @default.
• W2585750147 hasConceptScore W2585750147C2779823535 @default.
• W2585750147 hasConceptScore W2585750147C2780007613 @default.
• W2585750147 hasConceptScore W2585750147C2780923524 @default.
• W2585750147 hasConceptScore W2585750147C2781107101 @default.
• W2585750147 hasConceptScore W2585750147C2909962599 @default.
• W2585750147 hasConceptScore W2585750147C71924100 @default.
• W2585750147 hasConceptScore W2585750147C90924648 @default.
• W2585750147 hasIssue "11" @default.
• W2585750147 hasLocation W25857501471 @default.
• W2585750147 hasOpenAccess W2585750147 @default.
• W2585750147 hasPrimaryLocation W25857501471 @default.
• W2585750147 hasRelatedWork W2002667718 @default.

• next